Handelsbanken Fonder’s ImmunityBio IBRX Stock Holding History

Handelsbanken Fonder’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.39M	Sell	158,200 -18,700	-11%	-$142K	﹤0.01%	983
2026 Q1	$1.36M	Buy	176,900 +32,100	+22%	+$220K	﹤0.01%	904
2025 Q4	$287K	Buy	144,800 +48,800	+51%	+$111K	﹤0.01%	1442
2025 Q3	$236K	Hold	96,000	–	–	﹤0.01%	1466
2025 Q2	$253K	Buy	96,000 +3,700	+4%	+$9.95K	﹤0.01%	1462
2025 Q1	$278K	Hold	92,300	–	–	﹤0.01%	1428
2024 Q4	$236K	Buy	92,300 +38,400	+71%	+$160K	﹤0.01%	1495
2024 Q3	$201K	Hold	53,900	–	–	﹤0.01%	1493
2024 Q2	$341K	Buy	+53,900	New	+$355K	﹤0.01%	1331
2022 Q2	–	Sell	-26,900	Closed	-$151K	–	1651
2022 Q1	$151K	Hold	26,900	–	–	﹤0.01%	1662
2021 Q4	$164K	Buy	26,900 +10,900	+68%	+$81.9K	﹤0.01%	1724
2021 Q3	$156K	Hold	16,000	–	–	﹤0.01%	1664
2021 Q2	$228K	Buy	+16,000	New	+$264K	﹤0.01%	1681

Other funds holding IBRX

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Kercheville Advisors San Antonio, Texas $328M AUM 76.85% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

SSWM

Sheets Smith Wealth Management Winston-Salem, North Carolina $1B AUM 29.77% 1-Year Est. Return

LCGC

Legacy Capital Group California Los Gatos, California $332M AUM 42.15% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Plancorp LLC Saint Louis, Missouri $4.1B AUM 25.19% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

MWM

MFG Wealth Management Indianapolis, Indiana $140M AUM 44.72% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Handelsbanken Fonder's IBRX Position: Q2 2026 in Review

Handelsbanken Fonder reduced its ImmunityBio (IBRX) stake by 11% in Q2 2026, selling an estimated $142K and leaving 158,200 shares worth $1.39M. The position accounts for ﹤0.01% of the portfolio, ranked #983.

Handelsbanken Fonder first reported a position in IBRX in Q2 2021 and has held it in 13 quarters since. 128 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Handelsbanken Fonder held 158,200 shares of ImmunityBio worth $1.39M as of Q2 2026.
Handelsbanken Fonder sold 18,700 ImmunityBio shares in Q2 2026, an estimated $142K.
ImmunityBio made up ﹤0.01% of Handelsbanken Fonder's portfolio in Q2 2026, its #983 holding.
Handelsbanken Fonder first reported a position in ImmunityBio in Q2 2021 and has held it in 13 quarters since.
128 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.